Goodin DS, Frohman EM, Garmany GP Jr, Halper J., Likosky WH, Lublin FD et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology2002; 58: 169—78.
2.
Schellekens H.Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther2002; 24: 1720—40; discussion 1719.
3.
Wolinsky JS, Toyka KV, Kappos L., Grossberg SEInterferon-beta antibodies: implications for the treatment of MS. Lancet Neurol2003; 2: 528.
4.
Giovannoni G. , Munschauer FE3rd, Deisenhammer F. Neutralising antibodies to interferon beta during the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry2002; 73: 465—69.
5.
Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neurology1996; 47: 889—94.
6.
Cutter G.Statistical issues in neutralizing antibodies. Neurology2003; 61(Suppl 5): S38—39.
7.
Hartung HP, Munschauer F. 3rd, Schellekens H.Significance of neutralizing antibodies to interferon beta during treatment of multiple sclerosis: expert opinions based on the Proceedings of an International Consensus Conference. Eur J Neurol2005; 12: 588—601.
8.
Francis GS, Rice GP, Alsop JCInterferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology2005; 65: 48—55.
9.
Petkau AJ, White RA, Ebers GC, Reder AT, Sibley WA, Lublin FD et al. Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis. Mult Scler2004; 10: 126—38.
10.
Hemmer B., Stuve O., Kieseier B., Schellekens H., Hartung H-P.Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis. Lancet Neurol2005; 4: 403—12.
11.
Panitch H., Goodin DS, Francis G., Chang P., Coyle PK, O'Connor P. et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology2002; 59: 1496—506.
12.
PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology2001; 56: 1628—36.
13.
Bellomi F., Scagnolari C., Tomassini V., Gasperini C., Paolillo A., Pozzilli C. et al. Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years. J Neurol Sci2003; 215: 3—8.
14.
Rice GP, Paszner B., Oger J., Lesaux J., Paty D., Ebers G.The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b. Neurology1999; 52: 1277—79.
15.
Sorensen PS , Ross C., Clemmesen KM, Bendtzen K., Frederiksen JL, Jensen K. et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet2003; 362: 1184—91.
16.
Sorensen PS , Koch-Henriksen N., Ross C., Clemmesen KM, Bendtzen K.Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology2005; 65: 33—39.
17.
Polman CH, Kappos L., Petkau J., Thompson A.Neutralising antibodies to interferon beta during the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry2003 ; 74: 1162; author reply 1162—63.
18.
Gilli F., Bertolotto A., Sala A., Hoffmann F., Capobianco M., Malucchi S. et al. Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs. Brain2004; 127: 259—68.
